Pfizer (PFE) Data on Friday Should Be A Catalyst For Sarepta Therapeutics (SRPT) - Baird
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) ahead of Pfizer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
